Vertex Pharmaceuticals (MA) Reports Second Quarter 2013 Financial Results and Reviews Recent Progress and Upcoming Milestones in Clinical Development Programs

Published: Jul 30, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the quarter ended June 30, 2013. Vertex reported total second quarter 2013 revenues of $311 million, including net product revenues of $99 million from KALYDECOTM (ivacaftor) and $156 million from INCIVEKĀ® (telaprevir). The GAAP net loss attributable to Vertex was $(57.2) million, or $(0.26) per share, for the second quarter of 2013, including certain charges of $51.0 million, comprised primarily of stock-based compensation expense.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news